HGH Human Growth Hormone Replacement Therapy NYC » Stem Cell Therapy

Secrets of ailments unlocked by stem cells from skin samples

admin — Sun, 05 Feb 2012 16:43:29 +0000

The news that Edinburgh scientists had created the world's first cloned mammal, Dolly the sheep, at the university's Roslin Institute made headlines around the world 16 years ago.Her birth raised hopes of the creation of a new generation…Source:
http://news.search.yahoo.com/news/rss?p=stem+cells&ei=UTF-8&fl=0&x=wrt

Skin cells as stem cells

admin — Sun, 05 Feb 2012 16:43:29 +0000

BACKGROUND: Stem cells are the body's raw materials — cells from which all other cells with specialized functions are generated. Under the right conditions, stem cells divide to form more cells, called daughter cells. These daughter cells become new stem cells or specialized cells with a more specific function, such as blood cells, brain cells, heart muscle or bone. Stem cells are unique — no …Source:
http://news.search.yahoo.com/news/rss?p=stem+cells&ei=UTF-8&fl=0&x=wrt

Stem cells could drive hepatitis research forward

admin — Sun, 05 Feb 2012 16:43:29 +0000

Researchers have produced liver-like cells from induced pluripotent stem cells. By creating liver-like cells, scientists can study why people respond differently to Hepatitis C.Source:
http://news.search.yahoo.com/news/rss?p=stem+cells&ei=UTF-8&fl=0&x=wrt

Blacks urged to donate blood, stem cells

admin — Sun, 05 Feb 2012 16:43:29 +0000

An urgent shortage of blood and stem cells in the black community is costing lives, Canada's blood agency warns.Source:
http://news.search.yahoo.com/news/rss?p=stem+cells&ei=UTF-8&fl=0&x=wrt

Hepatitis Research May Benefit From Stem Cells

admin — Sun, 05 Feb 2012 16:43:29 +0000

Hepatitis C is a viral disease that leads to inflammation and organ failure. However, researchers are puzzled as to why some individuals are very susceptible to the disease, while others are not. Researchers believe they could find out how genetic variations produce these different responses by investigating liver cells from different individuals in the lab. However, liver cells are hard to …Source:
http://news.search.yahoo.com/news/rss?p=stem+cells&ei=UTF-8&fl=0&x=wrt

Adult stem cells testing offers promising results

admin — Sun, 05 Feb 2012 16:43:29 +0000

I must admit that, the more I read about what stem cells — especially adult (or "tis-sue") stem cells that are not under the current res-trictions on the use of embryonic stem cells — the more I am incredibly impressed at the growing successful results of the use of such stem cells, especially in trials where they have been so successful in research and testing results literally around the …Source:
http://news.search.yahoo.com/news/rss?p=stem+cells&ei=UTF-8&fl=0&x=wrt

Skin cells turned into neural precusors, bypassing stem-cell stage

admin — Sun, 05 Feb 2012 16:43:28 +0000

Mouse skin cells can be converted directly into cells that become the three main parts of the nervous system, according to researchers. The finding is an extension of a previous study by the same group showing that mouse and human skin cells can be directly converted into functional neurons.Source:
http://news.search.yahoo.com/news/rss?ei=UTF-8&p=IPS+stem+cells+therapy&eo=UTF-8

“Wide-ranging applications for pluripotent stem cells”

admin — Sun, 05 Feb 2012 16:43:28 +0000

Many more diseases can be targeted, says expertSource:
http://news.search.yahoo.com/news/rss?ei=UTF-8&p=IPS+stem+cells+therapy&eo=UTF-8

New era of medicine in the offing, says scientist

admin — Sun, 05 Feb 2012 16:43:28 +0000

Renowned Japanese scientist Shinya Yamanaka, who achieved a major breakthrough in the emerging area of stem cell research by creating a possible alternative to embryonic stem cells in 2007, express…Source:
http://news.search.yahoo.com/news/rss?ei=UTF-8&p=IPS+stem+cells+therapy&eo=UTF-8

Funding for Personalized Medicine Research

admin — Sun, 05 Feb 2012 16:43:28 +0000

The Cancer Stem Cell Consortium (CSCC) is a partner in the 2012 Large-Scale Applied Research Project Competition of Genome Canada, in collaboration with the first phase of the Personalized Medicine Signature Initiative of the Canadian Institutes of Health Research (CIHR). Genome Canada is leading the research competition. An excerpt from Fact Sheet: The Potential of Personalized Medicine:

Funding of $67.5M will come from Genome Canada ($40 million), CIHR ($22.5 million) and the Cancer Stem Cell Consortium ($5 million). Projects will be funded for a maximum of four years. To qualify for funding, researchers must obtain matching funding that at is least equal to that provided through the competition, which will bring the total investment in this research area to close to $140 million. Matching funding is typically derived from provincial, academic, private sector or international sources.

Details about the competition are available here.

Press releases, dated January 31, 2012, about the federal government’s support for personalized medicine, are available here and here.

Source:
http://cancerstemcellnews.blogspot.com/feeds/posts/default?alt=rss

Oxford, Harvard scientists lead data-sharing effort

admin — Sun, 05 Feb 2012 16:43:27 +0000

Led by researchers at University of Oxford (UK) and the Harvard Stem Cell Institute (HSCI) at Harvard University, (USA), more than 50 collaborators at over 30 scientific organizations around the globe have agreed on a common standard that will make possible the consistent description of enormous and radically different databases compiled in fields ranging from genetics to stem cell science, to environmental studies. (2012-01-30)Source:
http://www.brightsurf.com/rss.news.xml?search=Stem_Cells

MIT: Stem cells could drive hepatitis research forward

admin — Sun, 05 Feb 2012 16:43:27 +0000

Hepatitis C, an infectious disease that can cause inflammation and organ failure, has different effects on different people. But no one is sure why some people are very susceptible to the infection, while others are resistant. (2012-02-02)Source:
http://www.brightsurf.com/rss.news.xml?search=Stem_Cells

PRWEB: Absorption Systems Expands In Vivo Drug and Medical Device Testing Capabilities

admin — Sun, 05 Feb 2012 16:43:26 +0000

Preclinical contract research organization renovates facility, adding state-of-the-art technology and upgrading ocular testing services.

Exton, PA (PRWEB) January 31, 2012

Absorption Systems announces the latest in a series of milestones in the continuing expansion of its AAALAC-accredited and GLP-compliant facility in San Diego, CA. The facility is undergoing extensive renovations to upgrade and expand the company’s in vivo testing capabilities for drugs and medical devices, including the construction of a dedicated ocular testing laboratory with state-of-the-art equipment, including a Heidelberg Spectralis® optical coherence tomography (OCT) unit. This instrument produces detailed digital images of the retina, enabling precise monitoring of the efficacy and toxicity of drugs and medical devices. Absorption Systems’ San Diego facility, in the midst of a major expansion of staff, equipment, and capabilities in the specialized area of preclinical ocular drug and device testing, continues to see significant growth year-over-year early in 2012.

Glenwood Gum, M.S., Ph.D., who joined Absorption Systems in 2011 as Associate Director, Preclinical Studies, commented, “This OCT technology gives a huge boost to our ocular testing capabilities, which will immediately benefit our rapidly expanding client base.” Dr. Gum is an expert in preclinical ocular studies, having developed or co-developed many of the preclinical models of glaucoma, age-related macular degeneration (AMD), retinoblastoma, uveitis, and diabetic retinopathy that are used all over the world for drug testing. His expertise, along with dedicated staff and the addition of state-of-the-art equipment and facilities, are key to Absorption Systems’ strategy to aggressively pursue new business opportunities in the preclinical ocular testing arena.

Dr. Gum will be a featured speaker on Preclinical Glaucoma and CNV Models at the 4th Ocular Diseases and Drug Discovery conference in Las Vegas, NV February 27-28, 2012.

Patrick Dentinger, President and CEO of Absorption Systems, said, “For Absorption Systems, being a market leader in whatever endeavor we pursue is a cornerstone of our business philosophy. This requires scientific expertise, state-of-the-art equipment and facilities, and access to emerging technologies. These factors, combined with Absorption Systems’ customer-centric approach, make our commitment to being a top-tier ocular service provider a reality in 2012.”

Absorption Systems’ preclinical ocular test portfolio includes in vivo ocular pharmacokinetics, efficacy, and safety in multiple species, as well as in vitro ocular permeability and metabolism. For example, the human corneal orb is a unique in vitro permeability model available as a service platform only through Absorption Systems. The corneal orb, cultured from human pluripotent stem cells, was developed by Lifeline Cell Technology, Inc., a wholly-owned subsidiary of International Stem Cell Corporation, and has been validated by Absorption Systems as an in vitro corneal permeability test system.

About Absorption Systems
Absorption Systems, founded in 1996, assists pharmaceutical and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs and medical devices. The company’s mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. The CellPort Technologies® platform, a suite of human cell-based test systems for drug transporter characterization, exemplifies Absorption Systems’ commitment to innovation and is soon to be an industry assay standard for in vitro drug interaction assessment. Absorption Systems has facilities near Philadelphia, PA, and San Diego, CA, and serves customers throughout the world. For information on the company’s comprehensive contract services and applied research programs, please visit http://www.absorption.com.

SOURCE: http://www.prweb.com/releases/2012/1/prweb9153045.htm

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

Bonita stem cell doctor's attorney quits, state hearing still scheduled

admin — Sat, 04 Feb 2012 22:34:56 +0000

Dr. Zannos Grekos may not have an attorney representing him at a hearing next month against a state complaint that he performed an unauthorized stem cell procedure on a patient who later died.

Visit link:
Bonita stem cell doctor's attorney quits, state hearing still scheduled

stem cell therapy mexico, Successfully Results – Video

admin — Fri, 03 Feb 2012 14:02:08 +0000

www.youtube.com/watch?v=u4UrpSIHWxc

23-11-2011 02:11 For instance, neural cells in the brain and spinal cord that have been damaged can be replaced by stem cells. In the treatment of cancer, cells partially damaged by radiation or chemotherapy can be replaced with new healthy stem cells that adapt to the affected area, whether it be part of the brain, heart, liver, lungs, or wherever. Dead cells of almost any kind, no matter the type of injury or disease, can be replaced with new healthy cells thanks to the amazing flexibility of stem cells.

Read the original:
stem cell therapy mexico, Successfully Results – Video

BSGT-ESGCT What is Stem Cell Therapy? – Video

admin — Fri, 03 Feb 2012 06:22:03 +0000

www.youtube.com/watch?v=KRGvwrOALSQ

28-10-2011 17:23 Dr Tristan McKay of the William Harvey Research Institute at Queen Mary University of London presents the current status of stem cell therapies for human disease. He highlights the opportunities and controversies in the field, and sets out the challenges ahead. Hosted on Barts Cancer Institute Channel on behalf of Gene Therapy, Nature Specialist Journal Web links. Barts Cancer Institute: www.bci.qmul.ac.uk Gene Therapy, Nature Specialist Journal www.nature.com

Visit link:
BSGT-ESGCT What is Stem Cell Therapy? – Video

Calif. clinic licensed by controversial stem cell treatment group

admin — Thu, 02 Feb 2012 07:17:31 +0000

Doctors at a Southern California clinic have announced that they are “licensed and trained” to perform a stem cell treatment pioneered by a Colorado group that is being sued by the U.S. Justice Department and Food and Drug Administration .

Read the original:
Calif. clinic licensed by controversial stem cell treatment group

Athersys touts results of phase 1 blood diseases trial

admin — Thu, 02 Feb 2012 00:00:49 +0000

Stem cell therapy developer Athersys (NASDAQ:ATHX) reported positive results from a phase 1 clinical trial in patients with leukemia and similar blood diseases. The trial showed that the company’s MultiStem technology may reduce the incidence and severity graft-versus-host disease, according to a statement from Cleveland-based Athersys. Graft-versus-host disease (GvHD) often occurs after a stem …

Originally posted here:
Athersys touts results of phase 1 blood diseases trial

Athersys Announces Positive Results of MultiStem(R) Clinical Trial for Hematopoietic Stem Cell Transplant Support and …

admin — Thu, 02 Feb 2012 00:00:47 +0000

CLEVELAND — Athersys, Inc. today announced positive results from its Phase I clinical trial of MultiStem(R), its cell therapy product, administered to individuals undergoing allogeneic hematopoietic stem …

Experimental Neurology Journal: BrainStorm's NurOwn™ Stem Cell Technology Shows Promise for Treating Huntington's …

admin — Wed, 01 Feb 2012 18:42:54 +0000

NEW YORK & PETACH TIKVAH, Israel–(BUSINESS WIRE)– BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI.OB – News), a leading developer of adult stem cell technologies and therapeutics, announced today that the prestigious Experimental Neurology Journal, published an article indicating that preclinical studies using cells that underwent treatment with Brainstorm’s NurOwn™ technology show promise in an animal model of Huntington’s disease. The article was published by leading scientists including Professor Melamed and Professor Offen of the Tel Aviv University.

In these studies, bone marrow derived mesenchymal stem cells secreting neurotrophic factors (MSC-NTF), from patients with Huntington’s disease, were transplanted into the animal model of this disease and showed therapeutic improvement.

“The findings from this study demonstrate that stem cells derived from patients with a neurodegenerative disease, which are processed using BrainStorm’s NurOwn™ technology, may alleviate neurotoxic signs, in a similar way to cells derived from healthy donors. This is an important development for the company, as it confirms that autologous transplantation may be beneficial for such additional therapeutic indications,” said Dr. Adrian Harel, BrainStorm’s CEO.

“These findings provide support once again that BrainStorm’s MSC-NTF secreting cells have the potential to become a platform that in the future will provide treatment for various neuro-degenerative diseases,” says Chaim Lebovits, President of BrainStorm. “This study follows previously published pre-clinical studies that demonstrated improvement in animal models of neurodegenerative diseases such as Parkinson’s, Multiple Sclerosis (MS) and neural damage such as optic nerve transection and sciatic nerve injury. Therefore, BrainStorm will consider focusing on a new indication in the near future, in addition to the ongoing Clinical Trials in ALS.”

BrainStrom is currently conducting a Phase I/II Human Clinical Trial for Amyotrophic Lateral Sclerosis (ALS) also known as Lou Gehrig’s disease at the Hadassah Medical center. Initial results from the clinical trial (which is designed mainly to test the safety of the treatment), that were announced last week, have shown that the Brainstorm’s NurOwn™ therapy is safe and does not show any significant treatment-related adverse events and have also shown certain signs of beneficial clinical effects.

To read the Article entitled ‘Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: A potential therapy for Huntington's disease’ by Sadan et al. please go to:

http://www.sciencedirect.com/science/article/pii/S0014488612000295

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotech company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The company, through its wholly owned subsidiary Brainstorm Cell Therapeutics Ltd., holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The technology is currently in a Phase I/II clinical trials for ALS in Israel.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute “forward-looking statements” and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements, including, inter alia, regarding safety and efficacy in its human clinical trials and thereafter; the Company's ability to progress any product candidates in pre-clinical or clinical trials; the scope, rate and progress of its pre-clinical trials and other research and development activities; the scope, rate and progress of clinical trials we commence; clinical trial results; safety and efficacy of the product even if the data from pre-clinical or clinical trials is positive; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of our proposed product candidates; dependence on the efforts of third parties; failure by us to secure and maintain relationships with collaborators; dependence on intellectual property; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility, and risks that we may lack the financial resources and access to capital to fund our operations. The potential risks and uncertainties include risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect its technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. The Company does not undertake any obligation to update forward-looking statements made by us.

Follow this link:
Experimental Neurology Journal: BrainStorm's NurOwn™ Stem Cell Technology Shows Promise for Treating Huntington's …